AAPL341.07+5.15 (+1.53%) ▲|ABBV264.34-0.78 (-0.29%) ▼|ABT101.29+0.22 (+0.22%) ▲|ACN176.11-1.30 (-0.73%) ▼|ADBE235.47-3.46 (-1.45%) ▼|AMAT485.00+10.75 (+2.27%) ▲|AMD630.63+1.37 (+0.22%) ▲|AMGN414.61+8.57 (+2.11%) ▲|AMT169.03+1.77 (+1.06%) ▲|AMZN249.67+0.29 (+0.12%) ▲|AVGO352.81+2.45 (+0.70%) ▲|AXP308.89+3.23 (+1.06%) ▲|BA198.07+1.27 (+0.65%) ▲|BAC56.70+0.67 (+1.20%) ▲|BKNG163.95+6.54 (+4.15%) ▲|BLK1,086.31+12.86 (+1.20%) ▲|BMY62.86+1.36 (+2.21%) ▲|BNY150.15-0.04 (-0.03%) ▼|BRK-B505.48+0.30 (+0.06%) ▲|C134.28+2.18 (+1.65%) ▲|CAT821.58+16.33 (+2.03%) ▲|CL86.06+0.74 (+0.87%) ▲|CMCSA21.91-0.22 (-0.99%) ▼|COF200.20+3.59 (+1.83%) ▲|COP127.30-2.04 (-1.58%) ▼|COST922.77+26.29 (+2.93%) ▲|CRM234.02-4.20 (-1.76%) ▼|CSCO106.70-0.27 (-0.25%) ▼|CVS89.13+4.08 (+4.80%) ▲|CVX204.45-1.20 (-0.58%) ▼|DE690.46-4.48 (-0.64%) ▼|DHR224.49+0.72 (+0.32%) ▲|DIS106.15+0.59 (+0.56%) ▲|DUK113.35+0.12 (+0.11%) ▲|EMR158.23+2.09 (+1.34%) ▲|FDX285.85+6.31 (+2.26%) ▲|GD336.72+0.43 (+0.13%) ▲|GE327.09+7.31 (+2.29%) ▲|GEV957.63+2.59 (+0.27%) ▲|GILD150.93+1.24 (+0.83%) ▲|GM82.63+2.06 (+2.56%) ▲|GOOG341.08+2.07 (+0.61%) ▲|GOOGL343.92+1.56 (+0.46%) ▲|GS935.45+12.16 (+1.32%) ▲|HD293.20+1.02 (+0.35%) ▲|HON212.55+0.76 (+0.36%) ▲|IBM225.51-1.55 (-0.68%) ▼|INTC123.00-4.39 (-3.45%) ▼|INTU275.79-1.34 (-0.48%) ▼|ISRG405.18+5.66 (+1.42%) ▲|JNJ271.22+0.54 (+0.20%) ▲|JPM343.06+4.50 (+1.33%) ▲|KO87.81-0.29 (-0.33%) ▼|LIN469.89+1.75 (+0.37%) ▲|LLY1,183.46+1.57 (+0.13%) ▲|LMT519.56-4.14 (-0.79%) ▼|LOW189.28+0.79 (+0.42%) ▲|LRCX315.21+8.05 (+2.62%) ▲|MA567.65+1.57 (+0.28%) ▲|MCD236.50-0.52 (-0.22%) ▼|MDLZ60.25-0.61 (-1.00%) ▼|MDT88.64+0.85 (+0.97%) ▲|META751.66-25.93 (-3.33%) ▼|MMM169.55+2.03 (+1.21%) ▲|MO68.82-0.06 (-0.09%) ▼|MRK148.78+0.80 (+0.54%) ▲|MS196.31-0.01 (-0.01%) ▼|MSFT516.17+18.24 (+3.66%) ▲|MU1,082.28+1.75 (+0.16%) ▲|NEE76.08+0.46 (+0.61%) ▲|NFLX71.15-0.58 (-0.80%) ▼|NKE35.75-0.24 (-0.67%) ▼|NOW135.62-2.16 (-1.57%) ▼|NVDA225.07+0.49 (+0.22%) ▲|ORCL137.10-2.44 (-1.75%) ▼|PEP128.63+0.48 (+0.37%) ▲|PFE28.67+0.26 (+0.92%) ▲|PG146.23+0.55 (+0.38%) ▲|PLTR189.67-2.92 (-1.52%) ▼|PM190.48-1.02 (-0.53%) ▼|QCOM201.97+7.71 (+3.97%) ▲|RTX189.40+0.79 (+0.42%) ▲|SBUX94.86+1.21 (+1.29%) ▲|SCHW99.03-0.46 (-0.46%) ▼|SO82.88-0.01 (-0.01%) ▼|SPG204.82+0.12 (+0.06%) ▲|T25.38-0.07 (-0.28%) ▼|TMO675.00-3.39 (-0.50%) ▼|TMUS165.43+0.08 (+0.05%) ▲|TSLA372.11-5.83 (-1.54%) ▼|TXN278.07+7.42 (+2.74%) ▲|UBER69.62+0.40 (+0.58%) ▲|UNH376.59+1.58 (+0.42%) ▲|UNP273.79-0.28 (-0.10%) ▼|UPS93.96+1.91 (+2.08%) ▲|USB59.33+0.93 (+1.59%) ▲|V367.38-0.60 (-0.16%) ▼|VZ47.08-0.24 (-0.51%) ▼|WFC82.97+0.79 (+0.96%) ▲|WMT107.98+0.39 (+0.36%) ▲|XOM160.59-1.55 (-0.96%) ▼|AAPL341.07+5.15 (+1.53%) ▲|ABBV264.34-0.78 (-0.29%) ▼|ABT101.29+0.22 (+0.22%) ▲|ACN176.11-1.30 (-0.73%) ▼|ADBE235.47-3.46 (-1.45%) ▼|AMAT485.00+10.75 (+2.27%) ▲|AMD630.63+1.37 (+0.22%) ▲|AMGN414.61+8.57 (+2.11%) ▲|AMT169.03+1.77 (+1.06%) ▲|AMZN249.67+0.29 (+0.12%) ▲|AVGO352.81+2.45 (+0.70%) ▲|AXP308.89+3.23 (+1.06%) ▲|BA198.07+1.27 (+0.65%) ▲|BAC56.70+0.67 (+1.20%) ▲|BKNG163.95+6.54 (+4.15%) ▲|BLK1,086.31+12.86 (+1.20%) ▲|BMY62.86+1.36 (+2.21%) ▲|BNY150.15-0.04 (-0.03%) ▼|BRK-B505.48+0.30 (+0.06%) ▲|C134.28+2.18 (+1.65%) ▲|CAT821.58+16.33 (+2.03%) ▲|CL86.06+0.74 (+0.87%) ▲|CMCSA21.91-0.22 (-0.99%) ▼|COF200.20+3.59 (+1.83%) ▲|COP127.30-2.04 (-1.58%) ▼|COST922.77+26.29 (+2.93%) ▲|CRM234.02-4.20 (-1.76%) ▼|CSCO106.70-0.27 (-0.25%) ▼|CVS89.13+4.08 (+4.80%) ▲|CVX204.45-1.20 (-0.58%) ▼|DE690.46-4.48 (-0.64%) ▼|DHR224.49+0.72 (+0.32%) ▲|DIS106.15+0.59 (+0.56%) ▲|DUK113.35+0.12 (+0.11%) ▲|EMR158.23+2.09 (+1.34%) ▲|FDX285.85+6.31 (+2.26%) ▲|GD336.72+0.43 (+0.13%) ▲|GE327.09+7.31 (+2.29%) ▲|GEV957.63+2.59 (+0.27%) ▲|GILD150.93+1.24 (+0.83%) ▲|GM82.63+2.06 (+2.56%) ▲|GOOG341.08+2.07 (+0.61%) ▲|GOOGL343.92+1.56 (+0.46%) ▲|GS935.45+12.16 (+1.32%) ▲|HD293.20+1.02 (+0.35%) ▲|HON212.55+0.76 (+0.36%) ▲|IBM225.51-1.55 (-0.68%) ▼|INTC123.00-4.39 (-3.45%) ▼|INTU275.79-1.34 (-0.48%) ▼|ISRG405.18+5.66 (+1.42%) ▲|JNJ271.22+0.54 (+0.20%) ▲|JPM343.06+4.50 (+1.33%) ▲|KO87.81-0.29 (-0.33%) ▼|LIN469.89+1.75 (+0.37%) ▲|LLY1,183.46+1.57 (+0.13%) ▲|LMT519.56-4.14 (-0.79%) ▼|LOW189.28+0.79 (+0.42%) ▲|LRCX315.21+8.05 (+2.62%) ▲|MA567.65+1.57 (+0.28%) ▲|MCD236.50-0.52 (-0.22%) ▼|MDLZ60.25-0.61 (-1.00%) ▼|MDT88.64+0.85 (+0.97%) ▲|META751.66-25.93 (-3.33%) ▼|MMM169.55+2.03 (+1.21%) ▲|MO68.82-0.06 (-0.09%) ▼|MRK148.78+0.80 (+0.54%) ▲|MS196.31-0.01 (-0.01%) ▼|MSFT516.17+18.24 (+3.66%) ▲|MU1,082.28+1.75 (+0.16%) ▲|NEE76.08+0.46 (+0.61%) ▲|NFLX71.15-0.58 (-0.80%) ▼|NKE35.75-0.24 (-0.67%) ▼|NOW135.62-2.16 (-1.57%) ▼|NVDA225.07+0.49 (+0.22%) ▲|ORCL137.10-2.44 (-1.75%) ▼|PEP128.63+0.48 (+0.37%) ▲|PFE28.67+0.26 (+0.92%) ▲|PG146.23+0.55 (+0.38%) ▲|PLTR189.67-2.92 (-1.52%) ▼|PM190.48-1.02 (-0.53%) ▼|QCOM201.97+7.71 (+3.97%) ▲|RTX189.40+0.79 (+0.42%) ▲|SBUX94.86+1.21 (+1.29%) ▲|SCHW99.03-0.46 (-0.46%) ▼|SO82.88-0.01 (-0.01%) ▼|SPG204.82+0.12 (+0.06%) ▲|T25.38-0.07 (-0.28%) ▼|TMO675.00-3.39 (-0.50%) ▼|TMUS165.43+0.08 (+0.05%) ▲|TSLA372.11-5.83 (-1.54%) ▼|TXN278.07+7.42 (+2.74%) ▲|UBER69.62+0.40 (+0.58%) ▲|UNH376.59+1.58 (+0.42%) ▲|UNP273.79-0.28 (-0.10%) ▼|UPS93.96+1.91 (+2.08%) ▲|USB59.33+0.93 (+1.59%) ▲|V367.38-0.60 (-0.16%) ▼|VZ47.08-0.24 (-0.51%) ▼|WFC82.97+0.79 (+0.96%) ▲|WMT107.98+0.39 (+0.36%) ▲|XOM160.59-1.55 (-0.96%) ▼|
15.6 C
New York
Saturday, September 26, 2026

Tag: president

newssourceFORcompanyinformationcontent1releasesmarket

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal...

Prix Fitzgerald 2025 Laureate Announced at Hôtel Belles Rives

Renowned American Author Richard Ford Receives 14th Annual Literary Award for Be Mine 
Renowned American Author Richard Ford Receives 14th Annual Literary Award for Be Mine

Trump’s Steel Tariffs: Because Who Needs Affordable Appliances Anyway?

Ah, the Commerce Department strikes again, delivering yet another masterstroke in their ongoing saga of "How to Make Everything More Expensive for American Households."...

SL Benfica President Rui Costa Inaugurates Portuguese club’s new Residential Academy in Florida

The "Eagles" have taken their world-famous player development methodology to the United States TAMPA, Fla., June 14, 2025 /PRNewswire/ -- SL Benfica President Rui Costa...

GAC GS8 Traveller Edition Grand Launch Across Three Middle Eastern Nations, Strengthening Premium Mobility Market Strategy

RIYADH, Saudi Arabia, AMMAN, Jordan, and ERBIL, Iraq, June 14, 2025 /PRNewswire/ -- Recently, GAC intensified its Middle Eastern market layout: the GS8 Traveller premiered...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

ThinkCareBelieve: Week 21 of America’s Progress under President Trump

Washington D.C., June 14, 2025 (GLOBE NEWSWIRE) -- You can find the article here:  https://thinkcarebelieve.blog/2025/06/14/week-21-of-americas-progress-under-president-trump/

Sport Clips Haircuts Hosts National Signing Days

Recruiting Top Styling Talent Ready for the Big Leagues GEORGETOWN, Texas, June 14, 2025 /PRNewswire/ -- Styling professionals looking to take their careers to the next...

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

Aslan Energy Capital and JIEP Sign Heads of Agreement to Develop East Jakarta’s Renewable-Powered Hyperscale Data Center

JAKARTA, Indonesia, June 14, 2025 /PRNewswire/ -- Aslan Energy Capital (AEC), a Singapore-based developer of clean energy infrastructure, has signed a binding Heads of...

Xinhua Silk Road: 3rd Tianjin International Shipping Industry Expo kicks off to boost win-win cooperation

BEIJING, June 14, 2025 /PRNewswire/ -- The third Tianjin International Shipping Industry Expo (TISIE) kicked off in north China's Tianjin Municipality on Thursday, attracting the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPresident

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers